(Keynote) Continuous Glucose Monitoring Systems - Current Status and Future Perspectives of the Flagship Technologies in Biosensor Research -

Abstract

The history of the development of glucose sensors is synonym of the history of biosensor research. Glucose sensors created the past and current largest market in the industrialized biosensors. The most of the commercially available glucose sensors have been dedicated to the disposable sensor strips for self-monitoring of blood glucose (SMBG), thereby diabetic patients know which treatments and amounts of treatments to self-administer and to learn how activities affect their blood glucose levels. Currently, continuous glucose monitoring (CGM) systems have been recognized as the ideal monitoring systems for glycemic control of diabetic patients, expecting the replacement of SMBG sensors. Glucose monitoring using SMBG sensors requires taking tiny blood sample using a “lancet” to prick your finger or some other alternate sites for testing, whereas CGM systems monitor glucose level at interstitial fluid (ISF) where CGM sensor is inserted. At present, the glucose concentration in blood and ISF samples are recognized as the clinically relevant values. In 2018, the U.S. Food and Drug Administration (FDA) approved a medical device comprising CGM system, a continuous subcutaneous insulin infusion pump and a control algorithm that can supply an appropriate amount of basal insulin based on the CGM results as an artificial pancreas. Consequently, it became possible to automatically and continuously control the blood glucose level. In 2019, synthetic receptor employing long-term implantable CGM system, was approved as the prescription device, which realized up to 90 days (180 days in Europe) operation. These technological achievements boosted up CGM systems and sensors as the flagship technologies in the biosensor research.In this presentation, I will overview the current status and future perspectives of sensors for CGM systems.